

Giada Pontecorvi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1852813/publications.pdf>

Version: 2024-02-01

12
papers

218
citations

1162367

8
h-index

1199166

12
g-index

12
all docs

12
docs citations

12
times ranked

398
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex and Gender Disparities in Melanoma. <i>Cancers</i> , 2020, 12, 1819.	1.7	69
2	microRNAs as new possible actors in gender disparities of Covid-19 pandemic. <i>Acta Physiologica</i> , 2020, 230, e13538.	1.8	31
3	Tumor-derived extracellular vesicles and microRNAs: Functional roles, diagnostic, prognostic and therapeutic options. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 75-83.	3.2	25
4	SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma. <i>Oncotarget</i> , 2018, 9, 7567-7581.	0.8	17
5	The Sex-Related Interplay between TME and Cancer: On the Critical Role of Estrogen, MicroRNAs and Autophagy. <i>Cancers</i> , 2021, 13, 3287.	1.7	15
6	Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 2875.	1.7	14
7	Chronic Isolation Stress Affects Central Neuroendocrine Signaling Leading to a Metabolically Active Microenvironment in a Mouse Model of Breast Cancer. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 660738.	1.0	11
8	SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. <i>Oncogene</i> , 2022, 41, 4055-4065.	2.6	10
9	Autoantibodies Specific to ER \pm are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. <i>Cells</i> , 2019, 8, 750.	1.8	8
10	Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma. <i>Journal of Cell Communication and Signaling</i> , 2020, 14, 335-347.	1.8	8
11	pH-responsive oleic acid based nanocarriers: Melanoma treatment strategies. <i>International Journal of Pharmaceutics</i> , 2022, 613, 121391.	2.6	8
12	Different Susceptibilities of Human Melanoma Cell Lines to G2/M Blockage and Cell Death Activation in Response to the Estrogen Receptor β agonist LY500307. <i>Journal of Cancer</i> , 2022, 13, 1573-1587.	1.2	2